Key Acute Hepatic Porphyria Treatment Market Players:
- Alnylam Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mitsubishi Tanabe Pharma Corporation
- Recordati Rare Diseases
- Medunik USA
- Teva Pharmaceutical Industries Ltd.
- JCR Pharmaceuticals Co., Ltd.
- Pfizer Inc.
- Sanofi S.A.
- Fresenius Kabi AG
- Daiichi Sankyo Company, Limited
- Takeda Pharmaceutical Company Limited
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- CSL Limited
- Novartis AG
- Ipsen Pharma
- Mylan N.V. (now part of Viatris)
- Teijin Pharma Limited
Companies involved in the acute hepatic porphyria treatment market are focusing on regional expansion as each of them contributes to unique therapeutic approaches. With a collective aim of developing exclusive therapeutics, firms are leveraging different sorts of revenue-making opportunities. For example, Alnylam Pharmaceuticals leads with its RNA interference therapy, the U.S. FDA approved GIVLAARI (givosiran), for AHP treatment. Besides, companies such as Takeda, Pfizer, and F. Hoffmann-La Roche are investing in research and development to expand their product portfolios in the AHP sector. Hence, these strategies are boosting companies’ growth and maintaining competition in the market significantly.
Below is the list of some prominent players in the industry:
